ArticleCureus2024
Burden of Diabetes Mellitus in the Medically Underserved Rio Grande Valley.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Group-Based Trajectory Model to Assess Adjuvant Endocrine Therapy Adherence Pattern in HR-Positive Breast Cancer: Results from Rio Grande Valley Patients.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Diabetes mellitus (DM) encompasses metabolic disorders characterized by elevated blood sugar. This study aimed to evaluate the prevalence and associated metrics of DM in the Rio Grande Valley (RGV), a low-income and medically underserved region in the United States, and compare these metrics to the national averages from 2012 to 2022. Methods A retrospective cross-sectional analysis was conducted using publicly accessible data from the Centers for Medicare and Medicaid Services (CMS). Metrics analyzed included DM prevalence, average principal cost, rates of emergency department visits, hospitalizations, screenings, and prevalence of obesity. Data from the RGV counties were compared to national averages using Mann-Whitney U tests, with a p-value of <0.05 considered significant. Results From 2012 to 2022, DM affected patients in the RGV (43.95%) at significantly higher rates than the national average (26.73%) (p < 0.001). Obesity prevalence in the RGV was at higher rates than the national average (24.41% vs. 15.55%, p < 0.01). The screening rates of DM exceeded the national average (10.64% vs. 5.09%, p < 0.001). The average principal cost for patients in the RGV ($1,920.45) to treat DM was significantly greater than the national average principal cost ($859.64) (p < 0.001). The RGV also reported higher rates of ED visits (16.82 vs. 8.82 per 1,000 beneficiaries, p < 0.001) and hospitalizations (7.75 vs. 3.82 per 1,000 beneficiaries, p < 0.001). Conclusion The RGV exhibits significantly higher rates of DM and DM-associated metrics compared to the national averages, highlighting substantial public health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.